Copovidone (PVP-VA) Market Report 2026

The copovidone (PVP-VA) market size has grown strongly in recent years. It will grow from $1.08 billion in 2025 to $1.18 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing demand for oral solid dosage drugs and generics, growing need for solubility enhancers for poorly water-soluble active ingredients, rising development of advanced drug-delivery systems requiring high-performance binders, and increasing use of copovidone in film-coated and controlled-release formulations.

The copovidone (PVP-VA) market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to rising growth in cosmetics and personal-care formulations using versatile polymers, increasing interest in multifunctional excipients for food, nutraceutical and industrial applications, growing regulatory acceptance and quality standards favouring copovidone, and increasing investments in novel formulations leveraging copovidone. Major trends in the forecast period include advancement in use of copovidone for poorly water-soluble drugs via hot-melt extrusion and spray‐drying, innovation in controlled-release and solvent-free drug formulations, integration of copovidone in nutraceutical and cosmeceutical products, advancement of regulatory harmonisation facilitating global distribution, and innovation in multifunctional excipient blends combining copovidone with other polymers.

The rising demand for biopharmaceuticals is expected to drive growth in the copovidone (PVP-VA) market in the coming years. Biopharmaceuticals are therapeutic products developed using biological sources or biotechnology methods instead of conventional chemical synthesis. The surge in demand for biopharmaceuticals is driven by the growing prevalence of chronic and complex diseases, which increases the need for advanced targeted therapies that traditional drugs cannot adequately address. Copovidone (PVP-VA) supports this demand by offering versatile formulation and stabilizing properties, making it suitable for advanced drug delivery systems. It improves drug solubility, stability, and bioavailability, enhancing therapeutic effectiveness and supporting the development of innovative biopharmaceutical products. For instance, in June 2025, the Centers for Medicare & Medicaid Services (CMS), a US-based federal agency, reported that prescription drug expenditures increased 11.4% in 2023 to $449.7 billion, up from 7.8% growth in 2022. Consequently, the rising demand for biopharmaceuticals is fueling the growth of the copovidone (PVP-VA) market.

The growing prevalence of chronic diseases is expected to further propel the growth of the copovidone (PVP-VA) market. Chronic diseases are long-term health conditions that typically progress slowly, such as diabetes, heart disease, and arthritis, often requiring continuous medical care and lifestyle management to control symptoms and prevent complications. The rise in chronic diseases is largely attributed to unhealthy lifestyles, including poor diet, physical inactivity, and smoking, which increase the risk of diabetes, heart disease, and obesity. Copovidone (PVP-VA) supports chronic disease management as a versatile pharmaceutical excipient that enhances the stability, solubility, and bioavailability of medications. It boosts treatment effectiveness by enabling consistent drug delivery, promoting patient adherence, and facilitating advanced drug formulations for long-term disease control. For instance, in June 2024, the National Health Service, a UK-based government department, reported that 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the copovidone (PVP-VA) market.

Major companies in the copovidone (PVP-VA) market are focusing on developing advanced product grades and services, such as nitrite-tested grades, to improve regulatory compliance, enhance drug safety, and reduce nitrosamine risk. Nitrite-tested grades refer to enhanced quality assurance services for excipients, where each batch is tested for nitrites, potential precursors to nitrosamines, with results documented on the Certificate of Analysis. For example, in August 2025, BASF SE, a Germany-based chemical and materials company, launched Kollidon Nitrite Tested (NT) grades. This advanced service tier is designed to support customers’ nitrosamine control strategies by providing enhanced nitrite testing and documentation for key products, including Kollidon VA 64 NT. The service offers nitrite testing according to product specifications, with results reported on the Certificate of Analysis (CoA) for all delivered batches, adding an extra layer of quality assurance and documentation.

Major companies operating in the copovidone (pvp-va) market are BASF SE, Ashland Global Holdings Inc., Hangzhou Motto Science & Technology Co. Ltd., JRS Pharma GmbH & Co. KG, Boai NKY Pharmaceuticals Ltd., Anhui Sunhere Pharmaceutical Excipients Co. Ltd., Luxi Group Co. Ltd., Zhongbao Chemicals Co. Ltd., Autech Industry Co. Ltd., Huangshan Bonsun Pharmaceuticals Co. Ltd., Ningbo Inno Pharmchem Co. Ltd., Shanghai Yuking Water Soluble Material Technology Co. Ltd., Tianjin YR Chemspec Technology Co. Ltd., Star-Tech Specialty Products Co. Ltd., JH Nanhang Life Sciences Co. Ltd., Huzhou Sunflower Specialty Polymer Co. Ltd., Jiaozuo Zhongwei Special Products Pharmaceutical Co. Ltd., Ulanqab Kema New Material Co. Ltd., Sunfair PCS Polymer Material (Nanjing) Co. Ltd., Hefei Trendchem Co. Ltd.

North America was the largest region in the copovidone (PVP-VA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the copovidone (pvp-va) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the copovidone (pvp-va) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have influenced the copovidone market by increasing costs for imported raw materials, chemical intermediates, and polymer processing inputs, impacting overall excipient pricing. The effects are most notable in pharmaceutical and nutraceutical segments and in regions dependent on cross-border chemical supply chains such as Asia-Pacific and Europe. To offset these impacts, manufacturers are strengthening regional sourcing and optimizing production efficiencies. In some cases, tariffs have encouraged domestic excipient manufacturing and reduced reliance on imported polymers.

Copovidone (PVP-VA) is a synthetic polymer composed of vinylpyrrolidone and vinyl acetate, recognized for its superior solubility and film-forming capabilities. It is extensively used to improve the stability, bioavailability, and uniformity of active ingredients in formulations. Its versatility and compatibility with a wide range of compounds make it a crucial excipient in contemporary pharmaceutical and nutraceutical products.

The main types in the copovidone (PVP-VA) market include Copovidone, PVP-VA 64, and PVP-VA 73. Copovidone is a synthetic copolymer of vinylpyrrolidone and vinyl acetate, widely used as a binder, film-former, and solubilizer in pharmaceutical formulations due to its excellent compressibility, stability, and ability to enhance the bioavailability of poorly soluble drugs, making it an essential excipient in both solid and liquid dosage forms. Product forms include powder and liquid. Key applications span pharmaceuticals, cosmetics, food and beverage, adhesives, and coatings. The main distribution channels comprise direct sales, distributors, and online retailers.

The copovidone (PVP-VA) market consists of sales of bwf pharma copovidone, ashland copovidone klucel, basf copovidone vinol, cipla copovidone excipient, and dr. reddy’s copovidone powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.